The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 03, 2016

Filed:

Oct. 29, 2015
Applicant:

Astellas Pharma Inc., Tokyo, JP;

Inventors:

Hiromu Sato, Tokyo, JP;

Daisuke Yamajuku, Tokyo, JP;

Kazunori Arai, Tokyo, JP;

Mako Ogino, Tokyo, JP;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 5/07 (2010.01); C12N 5/00 (2006.01); C12P 21/06 (2006.01); C07H 21/04 (2006.01); C07K 16/00 (2006.01); C07K 16/28 (2006.01); C07K 14/715 (2006.01); C12P 21/02 (2006.01); C07K 16/24 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2866 (2013.01); C07K 14/715 (2013.01); C07K 16/244 (2013.01); C12P 21/02 (2013.01); A61K 2039/505 (2013.01); C07K 2317/40 (2013.01); C07K 2317/76 (2013.01); C07K 2319/30 (2013.01);
Abstract

[Problem] To provide an anti-human TSLP receptor antibody that specifically binds to human TSLP receptor and inhibits an action of human TSLP through human TSLP receptor. [Means for Solution] An anti-human TSLP receptor antibody had been studied by the present inventors, and an anti-human TSLP receptor antibody comprising a heavy chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 118 of SEQ ID NO: 1 and a light chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 108 of SEQ ID NO: 3 was provided. It was revealed that the anti-human TSLP receptor antibody inhibits expression of TARC mRNA induced by TSLP and production of MDC proteins, and suppressed an allergic reaction in a monkeyantigen sensitization model, and then the present invention was completed.


Find Patent Forward Citations

Loading…